Oncocyte is a precision diagnostics company focused on developing innovative tests that enhance patient care and improve outcomes. One of their key technologies is DetermaIO™, a proprietary gene expression test that evaluates the Tumor Immune Microenvironment (TIME) to identify patients who are most likely to benefit from immunotherapy. This test measures the expression levels of 27 genes, providing a comprehensive assessment that has shown strong associations with patient responses to immune checkpoint inhibitors across various cancer types, including advanced non-small cell lung cancer and triple-negative breast cancer. DetermaIO aims to address the limitations of standard PD-L1 testing, which often misidentifies potential responders, thereby reducing unnecessary treatment costs and adverse events for patients unlikely to benefit from such therapies.

In addition to DetermaIO, Oncocyte is committed to developing a suite of diagnostic tests that provide actionable insights at critical decision points in patient care. Their offerings include tests for early detection of cancer progression post-treatment and monitoring the health of kidney and liver transplants through the analysis of donor-derived cell-free DNA. By focusing on personalized diagnostics, Oncocyte seeks to empower healthcare providers with the tools necessary to make informed decisions, ultimately leading to better patient outcomes throughout the cancer care continuum.

United States

Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions. They are focused on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

Oncocyte

Company Details